ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 387,76
0,85%
DAX
18 686,60
1,07%
Brent Oil
83,985
0,51%
Bitcoin
62 438,57
2,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. HUTCHMED China Limited (HCM)

  7. HUTCHMED China Limited (HCM) Actualités

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HCM
DateHeureSourceTitreSymboleSociété
08/05/202410h30GlobeNewswire Inc.HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNASDAQ:HCMHUTCHMED China Limited
26/04/202414h30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
05/04/202410h30GlobeNewswire Inc.HUTCHMED Highlights Data to be Presented at AACR Congress 2024NASDAQ:HCMHUTCHMED China Limited
02/04/202406h30GlobeNewswire Inc.HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
28/03/202401h00GlobeNewswire Inc.HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCNASDAQ:HCMHUTCHMED China Limited
22/03/202401h00GlobeNewswire Inc.HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaNASDAQ:HCMHUTCHMED China Limited
05/03/202412h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
28/02/202412h40Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:HCMHUTCHMED China Limited
28/02/202412h30GlobeNewswire Inc.HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
07/02/202401h00GlobeNewswire Inc.HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionNASDAQ:HCMHUTCHMED China Limited
02/02/202409h30GlobeNewswire Inc.HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipNASDAQ:HCMHUTCHMED China Limited
01/02/202409h30GlobeNewswire Inc.HUTCHMED to Announce 2023 Final ResultsNASDAQ:HCMHUTCHMED China Limited
30/01/202405h53GlobeNewswire Inc.HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
11/01/202401h00GlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
13/12/202305h30GlobeNewswire Inc.HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsNASDAQ:HCMHUTCHMED China Limited
13/12/202301h00GlobeNewswire Inc.HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaNASDAQ:HCMHUTCHMED China Limited
01/12/202301h00GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNASDAQ:HCMHUTCHMED China Limited
10/11/202314h35GlobeNewswire Inc.Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingNASDAQ:HCMHUTCHMED China Limited
09/11/202301h11GlobeNewswire Inc.HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
01/11/202313h35GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary ReceiptsNASDAQ:HCMHUTCHMED China Limited
16/10/202310h30GlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023NASDAQ:HCMHUTCHMED China Limited
29/09/202310h30GlobeNewswire Inc.HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in JapanNASDAQ:HCMHUTCHMED China Limited
12/09/202310h30GlobeNewswire Inc.HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung CancerNASDAQ:HCMHUTCHMED China Limited
12/09/202302h00GlobeNewswire Inc.HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ChinaNASDAQ:HCMHUTCHMED China Limited
29/08/202302h00GlobeNewswire Inc.HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric CancerNASDAQ:HCMHUTCHMED China Limited
21/08/202302h00GlobeNewswire Inc.HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in ChinaNASDAQ:HCMHUTCHMED China Limited
31/07/202313h41GlobeNewswire Inc.HUTCHMED Reports 2023 Interim Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
20/07/202302h00GlobeNewswire Inc.HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration StudyNASDAQ:HCMHUTCHMED China Limited
13/07/202310h30GlobeNewswire Inc.HUTCHMED Announces Changes to Board of Directors and Technical Committee NASDAQ:HCMHUTCHMED China Limited
10/07/202302h00GlobeNewswire Inc.HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in ChinaNASDAQ:HCMHUTCHMED China Limited
 Showing the most relevant articles for your search:NASDAQ:HCM

Dernières Valeurs Consultées

EU
GLE
Societe Generale
NYSE
DIS
Walt Disney
EU
PX1
CAC 40
NYSE
MCD
McDonalds
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
EU
PX4
SBF 120
EU
BN
Danone
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
EU
SGO
Cie de SaintGobain
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés